Literature DB >> 2210449

Soluble interleukin-2 receptor in Crohn's disease: relation of serum concentrations to disease activity.

J E Crabtree1, L D Juby, R V Heatley, A J Lobo, D W Bullimore, A T Axon.   

Abstract

Serum concentrations of soluble interleukin-2 receptor (sIL-2R) were measured as a marker of immune activation in a group of 30 patients with Crohn's disease. sIL-2R concentrations were determined by enzyme linked immunosorbent assay during periods of active and inactive disease and correlated with standard parameters of disease activity. Serum concentrations of sIL-2R were significantly raised in patients with active Crohn's disease compared with patients with inactive disease (p less than 0.001) and control subjects. There was a significant correlation between serum sIL-2R concentrations and disease activity as assessed by the Harvey-Bradshaw index (r = 0.42, p less than 0.01), platelet numbers (r = 0.49, p less than 0.01), and orosomucoid (r = 0.47, p less than 0.01), alpha 1 antitrypsin (r = 0.44, p less than 0.01), and C reactive protein concentrations (r = 0.48, p less than 0.001) but not with the erythrocyte sedimentation rate. Measurement of serum sIL-2R concentration is a simple and useful laboratory means of assessing disease activity. Raised concentrations in patients with active Crohn's disease is further evidence for in vivo immune activation occurring in this disease.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2210449      PMCID: PMC1378664          DOI: 10.1136/gut.31.9.1033

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  28 in total

1.  A simple index of Crohn's-disease activity.

Authors:  R F Harvey; J M Bradshaw
Journal:  Lancet       Date:  1980-03-08       Impact factor: 79.321

2.  A monoclonal antibody 7G7/B6, binds to an epitope on the human interleukin-2 (IL-2) receptor that is distinct from that recognized by IL-2 or anti-Tac.

Authors:  L A Rubin; C C Kurman; W E Biddison; N D Goldman; D L Nelson
Journal:  Hybridoma       Date:  1985

3.  Intestinal lymphocyte subpopulations in inflammatory bowel disease: an analysis by immunohistological and cell isolation techniques.

Authors:  W S Selby; G Janossy; M Bofill; D P Jewell
Journal:  Gut       Date:  1984-01       Impact factor: 23.059

Review 4.  Why study T cell subsets in Crohn's disease?

Authors:  A Ferguson
Journal:  Gut       Date:  1983-08       Impact factor: 23.059

5.  Involvement of the immune system in the pathogenesis of Crohn's disease. Expression of the T9 antigen on peripheral immunocytes correlates with the severity of the disease.

Authors:  A Raedler; S Fraenkel; G Klose; K Seyfarth; H G Thiele
Journal:  Gastroenterology       Date:  1985-04       Impact factor: 22.682

6.  Characterization of the human receptor for T-cell growth factor.

Authors:  W J Leonard; J M Depper; R J Robb; T A Waldmann; W C Greene
Journal:  Proc Natl Acad Sci U S A       Date:  1983-11       Impact factor: 11.205

7.  Suppression of immunoglobulin synthesis by lymphocyte subpopulations in patients with Crohn's disease.

Authors:  S P James; L M Neckers; A S Graeff; J Cossman; C M Balch; W Strober
Journal:  Gastroenterology       Date:  1984-06       Impact factor: 22.682

8.  Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro.

Authors:  L A Rubin; C C Kurman; M E Fritz; W E Biddison; B Boutin; R Yarchoan; D L Nelson
Journal:  J Immunol       Date:  1985-11       Impact factor: 5.422

9.  Covert suppressor T cells in Crohn's disease.

Authors:  C O Elson; A S Graeff; S P James; W Strober
Journal:  Gastroenterology       Date:  1981-06       Impact factor: 22.682

10.  Expression of interleukin 2 receptors on activated human B cells.

Authors:  T A Waldmann; C K Goldman; R J Robb; J M Depper; W J Leonard; S O Sharrow; K F Bongiovanni; S J Korsmeyer; W C Greene
Journal:  J Exp Med       Date:  1984-11-01       Impact factor: 14.307

View more
  19 in total

Review 1.  Current advantages in the application of proteomics in inflammatory bowel disease.

Authors:  Anna Vaiopoulou; Maria Gazouli; George Theodoropoulos; George Zografos
Journal:  Dig Dis Sci       Date:  2012-06-28       Impact factor: 3.199

2.  Protein microarray analysis of disease activity in pediatric inflammatory bowel disease demonstrates elevated serum PLGF, IL-7, TGF-beta1, and IL-12p40 levels in Crohn's disease and ulcerative colitis patients in remission versus active disease.

Authors:  Howard A Kader; Velizar T Tchernev; Ebenezer Satyaraj; Serguei Lejnine; Gregory Kotler; Stephen F Kingsmore; Dhavalkumar D Patel
Journal:  Am J Gastroenterol       Date:  2005-02       Impact factor: 10.864

Review 3.  Production of inflammatory cytokines in the intestinal lamina propria.

Authors:  C Fiocchi
Journal:  Immunol Res       Date:  1991       Impact factor: 2.829

4.  Cytokine production in patients with inflammatory bowel disease.

Authors:  M Nakamura; H Saito; J Kasanuki; Y Tamura; S Yoshida
Journal:  Gut       Date:  1992-07       Impact factor: 23.059

Review 5.  Pathogenetic and clinical relevance of cytokines in inflammatory bowel disease.

Authors:  R B Sartor
Journal:  Immunol Res       Date:  1991       Impact factor: 2.829

Review 6.  Neutrophil autoantibodies as disease markers for ulcerative colitis.

Authors:  F Shanahan; C Landers; R Duerr; S R Targan
Journal:  Immunol Res       Date:  1991       Impact factor: 2.829

7.  Soluble interleukin-2 receptor in Crohn's disease. Assessment of disease activity and prediction of relapse.

Authors:  E Louis; J Belaiche; C Van Kemseke; N Schaaf; P Mahieu; J Y Mary
Journal:  Dig Dis Sci       Date:  1995-08       Impact factor: 3.199

8.  Oral 4-aminosalicylic acid versus 5-aminosalicylic acid slow release tablets. Double blind, controlled pilot study in the maintenance treatment of Crohn's ileocolitis.

Authors:  S Schreiber; S Howaldt; A Raedler
Journal:  Gut       Date:  1994-08       Impact factor: 23.059

9.  Increased in vitro release of soluble interleukin 2 receptor by colonic lamina propria mononuclear cells in inflammatory bowel disease.

Authors:  S Schreiber; A Raedler; A R Conn; J L Rombeau; R P MacDermott
Journal:  Gut       Date:  1992-02       Impact factor: 23.059

10.  Increased spontaneous secretion of rheumatoid factor by intestinal lamina propria mononuclear cells from Crohn's disease but not ulcerative colitis patients.

Authors:  R P MacDermott; S Schreiber; G S Nash; W J Koopman
Journal:  Clin Exp Immunol       Date:  1993-04       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.